Harmaline

Harmaline
Clinical data
Other names7-Methoxyharmalan; 7-MeO-harmalan; 7-OMe-harmalan; 7-Methoxy-3,4-dihydroharman; 3,4-Dihydroharmine; 3,4-Dihydro-7-methoxy-1-methyl-β-carboline; Harmadine
Routes of
administration
Oral, intravenous
Drug classHallucinogen; Oneirogen; Monoamine oxidase inhibitor; Reversible inhibitor of MAO-A
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Onset of actionOral: 1–2 hours
IVTooltip Intravenous injection: Seconds
Elimination half-life2 hours
Duration of actionOral: 5–8 hours
IV: "Much shorter" (than oral)
Identifiers
  • 7-methoxy-1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.005.594
Chemical and physical data
FormulaC13H14N2O
Molar mass214.268 g·mol−1
3D model (JSmol)
Melting point232 to 234 °C (450 to 453 °F)
  • COc3ccc2c1CCN=C(C)c1[nH]c2c3
  • InChI=1S/C13H14N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-4,7,15H,5-6H2,1-2H3 checkY
  • Key:RERZNCLIYCABFS-UHFFFAOYSA-N checkY
  (verify)

Harmaline, also known as 7-methoxyharmalan or as 3,4-dihydro-7-methoxy-1-methyl-β-carboline, is a harmala alkaloid and β-carboline which has hallucinogenic effects and monoamine oxidase inhibitor (MAOI) activity. It is the partly hydrogenated form of harmine.

Plants containing harmaline are combined in ayahuasca to inhibit monoamine oxidase (MAO), allowing orally consumed dimethyltryptamine (DMT) to become orally active and produce psychoactive effects. Harmala alkaloids, including harmaline, are psychoactive on their own in humans, with harmaline being particularly hallucinogenic, although other compounds such as harmine and tetrahydroharmine (THH) have also been reported to produce hallucinogenic effects as well.

Harmaline is present in Peganum harmala (Syrian rue). Syrian rue seeds contain about 3% harmala alkaloids by dry weight. Harmaline was first isolated from plants in 1841, its chemical structure identified in 1919, and it was first synthesized in 1927.